22. もやもや病 Moyamoya disease Clinical trials / Disease details
臨床試験数 : 17 / 薬物数 : 22 - (DrugBank : 17) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 45
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs071220048 | 29/08/2022 | 29/08/2022 | Angiogenesis augmentation therapy for indirect revascularization of moyamoya disease using G-CSF | Angiogenesis augmentation therapy for indirect revascularization of moyamoya disease using G-CSF - EDFAPS-G | Moyamoya disease Moyamoya disease, indirect revascularization, Granulocyte-Colony Stimulating Factor;D009072 | G-CSF(75 micrograms/body) is applied intraoperatively to the indirect revascularization site, and G-CSF (75 micrograms/body) is given intravenously once daily for 2 days. | Morioka Motohiro | NULL | Recruiting | >= 20age old | <= 60age old | Both | 5 | Phase 1-2 | Japan |
| 2 | ChiCTR2100050185 | 2021-08-23 | 2021-08-21 | Effect of stellate ganglion block on intracranial vascular and prognosis in patients with Moyamoya disease | Effect of stellate ganglion block on intracranial vascular and prognosis in patients with Moyamoya disease | Moyamoya disease | SGB group:Ipsilateral stellate ganglion block was performed with 0.2% ropivacaine 8ml;control group:Routine extracranial artery bypass grafting only; | The First Affiliated Hospital of Sun Yat-sen University | NULL | Pending | 12 | 65 | Both | SGB group:12;control group:12; | Phase 1 | China |
| 3 | ChiCTR2100050015 | 2021-08-12 | 2021-08-15 | Effect of stellate ganglion block on intracranial vascular and stress level in patients with Moyamoya disease | Effect of stellate ganglion block on intracranial vascular and stress level in patients with Moyamoya disease | Moyamoya disease | stellate ganglion group:1.5% lidocaine planetary ganglion block; control group:DSA only, no stellate ganglion block; | the First Affiliated Hospital of Sun Yat-Sen University | NULL | Pending | 12 | 65 | Both | stellate ganglion group:12; control group:12; | China | |
| 4 | ChiCTR2100046178 | 2021-05-10 | 2021-05-08 | Efficacy and safety of antiplatelet drugs in patients with moyamoya disease after revascularization | Efficacy and safety of antiplatelet drugs in patients with moyamoya disease after revascularization | Moyamoya disease | Taking aspirin group:Nil;No aspirin group:Nil; | Qilu Hospital of Shandong University | NULL | Recruiting | 0 | 60 | Both | Taking aspirin group:105;No aspirin group:105; | china | |
| 5 | JPRN-jRCTs031200402 | 23/04/2021 | 08/03/2021 | Search for abnormalities of fundus blood vessels in moyamoya disease | Search for abnormalities of fundus blood vessels in moyamoya disease | Moyamoya disease Moyamoya disease | For fluorescein fundus angiography, 500 mg of fluorescein (5 ml vial of aqueous solution containing 500 mg of fluorescein) and 25 mg of Ophthagreen (2 ml of blue indocyanine green) are dissolved in 2 ml of distilled water for injection and injected through the forearm of the elbow vein. In daily practice, diabetic retinopathy can be treated by using a diabetic retinal imaging system (optos). In daily practice, it is used for the diagnosis of diabetic retinopathy, uveitis, occlusive retinal vascular disease, and age-related macular degeneration. | Akiyama Hideo | NULL | Recruiting | >= 20age old | Not applicable | Both | 50 | N/A | Japan |
| 6 | ChiCTR2000041260 | 2021-01-01 | 2020-12-23 | The effects of norepinephrine and phenylephrine on cerebral oxygenation in treating intraoperative hypotension in STA-MCA bypass surgery | The effects of norepinephrine and phenylephrine on cerebral oxygenation in treating intraoperative hypotension in STA-MCA bypass surgery | moyamoya disease | Group 1:iv norepinephrine;Group 2:iv phenylephrine; | The South District of Anhui Provincial Hospital | NULL | Recruiting | 18 | 65 | Both | Group 1:30;Group 2:30; | Phase 4 | China |
| 7 | ChiCTR2000029878 | 2020-11-01 | 2020-02-16 | The effects of norepinephrine and phenylephrine on cerebral oxygenation in treating intraoperative hypotension in STA-MCA bypass surgery | The effects of norepinephrine and phenylephrine on cerebral oxygenation in treating intraoperative hypotension in STA-MCA bypass surgery | moyamoya disease | Group 1:iv norepinephrine;Group 2:iv phenylephrine; | The South District of Anhui Provincial Hospital | NULL | Pending | 18 | 65 | Both | Group 1:30;Group 2:30; | Phase 4 | China |
| 8 | NCT04205578 (ClinicalTrials.gov) | January 2020 | 18/12/2019 | NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events | A Multi-center, Randomized, Single-blind, Placebo-controlled Study of Dl-3-n-butylphthalide in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events After Extracranial-to-intracranial Revascularization Surgery | Moyamoya Disease;Ischemic Cerebral Infarction;Ischemic Stroke;Ischemic Cerebrovascular Accident;Transient Ischemic Attack | Drug: dl-3-n-butylphthalide (NBP);Drug: Normal Saline 0.9% Infusion Solution | yuanli Zhao | Peking University International Hospital | Not yet recruiting | 18 Years | 60 Years | All | 450 | Phase 3 | China |
| 9 | NCT04012268 (ClinicalTrials.gov) | July 15, 2019 | 3/7/2019 | The Safety and Efficacy of RIC on Adult Moyamoya Disease | The Safety and Effect of Remote Ischemic Conditioning on Adult Moyamoya Disease | Moyamoya Disease | Device: RIC;Drug: Aspirin | Capital Medical University | NULL | Completed | 18 Years | 60 Years | All | 30 | N/A | China |
| 10 | ChiCTR1900027197 | 2019-05-01 | 2019-11-04 | Study on the protective effect of desflurane combined with propofol on the brain of patients with moyamoya disease undergoing cerebral revascularization | Study for the protective effect of desflurane on the brain of patients with moyamoya disease | Moyamoya disease | Group D:Desflurane for anesthesia maintenance;GroupP:Propofol;GroupPD:Desflurane and propofol; | The First Affiliated Hospital of Zhengzhou University | NULL | Completed | 20 | 65 | Both | Group D:30;GroupP:30;GroupPD:30; | Phase 4 | China |
| 11 | NCT03882060 (ClinicalTrials.gov) | April 8, 2019 | 12/3/2019 | Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya Patients | The Effect of Recombinant Human Erythropoietin on the Postoperative Neurologic Outcome in Pediatric Moyamoya Disease Patients - A Double Blind Randomized Controlled Trial | Moyamoya Disease;Pediatrics;Cerebrovascular Disorders | Drug: erythropoietin;Drug: Normal saline | Seoul National University Hospital | NULL | Active, not recruiting | N/A | 18 Years | All | 60 | N/A | Korea, Republic of |
| 12 | ChiCTR1800020377 | 2019-01-01 | 2018-12-27 | Aspirin in Moyamoya Disease | The Clinical Benefit and Risk of Oral Aspirin for Moyamoya Disease | moyamoya disease | Case series:Aspirin; | Beijing Tiantan Hospital, Capital Medical University | NULL | Recruiting | 8 | 60 | Both | Case series:300; | China | |
| 13 | JPRN-jRCTs031180017 | 01/08/2018 | 07/09/2018 | Studies on the utility of simultaneous-multi-slice acquisition (SMS) dynamic susceptibility contrast-enhanced (DSC)MRI for the occulusive cerebrobascular disease | Studies on the utility of simultaneous-multi-slice acquisition (SMS) dynamic susceptibility contrast-enhanced (DSC)MRI for the occulusive cerebrobascular disease - SMS DSC-MRI study for the occulusive cerebrobascular disease | carotid artery stenosis, moyamoya disease | Intravenous administration of gadobutrol (Gadovist, Bayer Schering Pharma, Berlin, Germany) is administered in the supine position, and high speed DSC-MRI scan by using SMS acquisition (temporal resolution of 0.5s) is carried out at the same time as injection of the contrast agent with an acquisition time of 70sec. The quantitative and qualitative comparison between reference data set (0.5s) and additional data sets with temporal resolution of 1.0s, 1.5s, and 2.0s generated from the reference data set, is performed. | Aoki Shigeki | Bayer Yakuhin, Ltd;Bayer Yakuhin, Ltd | Complete | >= 20age old | Not applicable | Both | 50 | N/A | Japan |
| 14 | NCT02510586 (ClinicalTrials.gov) | August 2015 | 24/7/2015 | Sevoflurane and Hyperperfusion Syndrome | Effect of Sevoflurane-induced Postconditioning on the Incidence of Postoperative Cerebral Hyperperfusion Syndrome After Revascularization Surgery in Adult Patients With Moyamoya Disease | Hyperperfusion Syndrome;Moyamoya Disease | Drug: Sevoflurane | Seoul National University Hospital | NULL | Not yet recruiting | 18 Years | N/A | Both | 152 | N/A | NULL |
| 15 | JPRN-UMIN000008742 | 2012/09/01 | 21/08/2012 | Studies on the effect of free radical scavenger Edaravone against postoperative hyper-perfusion syndrome after STA-MCA bypass surgery for adult moyamoya disease. | Studies on the effect of free radical scavenger Edaravone against postoperative hyper-perfusion syndrome after STA-MCA bypass surgery for adult moyamoya disease. - Studies on the effect of free radical scavenger Edaravone against postoperative hyper-perfusion syndrome after STA-MCA bypass surgery for adult moyamoya disease. | moyamoya disease | Administration of edaravone from preoperative to postoperative day 7. | Department of Neurosurgery, Hokkaido University Graduate School of Medicine | NULL | Complete: follow-up complete | 16years-old | Not applicable | Male and Female | 32 | Not applicable | Japan |
| 16 | NCT03162588 (ClinicalTrials.gov) | May 1, 2010 | 18/5/2017 | Multiple Burrhole Therapy With Erythropoietin for Unstable Moyamoya | Feasibility Study of Multiple Burrhole Therapy Combined With Intravenous Erythropoietin Pretreatment for Unstable Moyamoya | Ischemic Attack;Ischemic Stroke;Moyamoya Disease;Burr Hole;Angiogenesis | Drug: erythropoietin | Ajou University School of Medicine | NULL | Completed | 16 Years | N/A | All | 37 | Phase 1/Phase 2 | Korea, Republic of |
| 17 | NCT01419275 (ClinicalTrials.gov) | April 2009 | 16/8/2011 | Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients | Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients | Cerebrovascular Accident;Moyamoya Disease | Drug: Xenon contrast agent;Device: Magnetic Resonance Imaging | Stanford University | NULL | Completed | N/A | N/A | All | 126 | N/A | United States |